文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Meningitis.多药耐药性脑膜炎治疗期间头孢洛扎与他唑巴坦的血浆和脑脊液治疗药物监测

Open Forum Infect Dis. 2020 Nov 12;7(12):ofaa549. doi: 10.1093/ofid/ofaa549. eCollection 2020 Dec.

2

Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.患者患有多重耐药铜绿假单胞菌脑膜炎，连续输注头孢他洛滨-他唑巴坦可使头孢他洛滨在脑脊液中达到高浓度。

Infection. 2021 Apr;49(2):355-359. doi: 10.1007/s15010-020-01510-8. Epub 2020 Aug 29.

3

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.头孢洛扎他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合，对多种耐药性革兰氏阴性杆菌具有活性。

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.

4

Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.成功使用头孢洛扎/他唑巴坦治疗由多重耐药铜绿假单胞菌引起的囊性纤维化肺部加重期

Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1.

5

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。

Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.

6

Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.头孢他啶/他唑巴坦单独及联合黏菌素对体外生物膜药效模型中多重耐药铜绿假单胞菌的疗效。

Int J Antimicrob Agents. 2019 May;53(5):612-619. doi: 10.1016/j.ijantimicag.2019.01.010. Epub 2019 Jan 23.

7

Association of , ,   and β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant .多药耐药菌中 blaKPC、blaNDM、blaIMP 和 blaVIM 与对头孢他啶-阿维巴坦及头孢洛扎坦-他唑巴坦耐药的相关性

Antibiotics (Basel). 2022 Jan 19;11(2):130. doi: 10.3390/antibiotics11020130.

8

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。

J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.

9

Evaluation of activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against and -the EM200 study.头孢洛扎/他唑巴坦与其他类抗菌药物联合应用对[具体对象]的活性评估及EM200研究

New Microbes New Infect. 2021 Mar 19;41:100872. doi: 10.1016/j.nmni.2021.100872. eCollection 2021 May.

10

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.解析铜绿假单胞菌头孢他啶-他唑巴坦耐药性的演变。

mBio. 2018 Dec 11;9(6):e02085-18. doi: 10.1128/mBio.02085-18.

引用本文的文献

1

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.用于治疗医院获得性中枢神经系统感染的新型抗生素

Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058.

2

The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults.血脑屏障与治疗成人中枢神经系统感染抗生素的药代动力学/药效学优化

Antibiotics (Basel). 2022 Dec 19;11(12):1843. doi: 10.3390/antibiotics11121843.

3

Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.治疗药物监测和头孢他啶/他唑巴坦长时间输注治疗多重耐药/广泛耐药铜绿假单胞菌感染：一项观察性研究。

Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):561-566. doi: 10.1007/s13318-022-00772-x. Epub 2022 Jun 3.

4

Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis.医疗保健相关脑室炎和脑膜炎诊断与管理的当前观点

Infect Drug Resist. 2022 Feb 28;15:697-721. doi: 10.2147/IDR.S326456. eCollection 2022.

5

Augmented Renal Clearance: What Have We Known and What Will We Do?增强肾清除率：我们已知什么以及我们将做什么？

Front Pharmacol. 2021 Nov 2;12:723731. doi: 10.3389/fphar.2021.723731. eCollection 2021.

本文引用的文献

1

Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain.颅内感染患者留置脑室外引流管时脑脊液中头孢他啶-他唑巴坦的渗透情况。

Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01698-20.

2

Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam.利用治疗药物监测指导头孢他啶/阿维巴坦治疗产KPC的中枢神经系统感染

Open Forum Infect Dis. 2020 Aug 18;7(9):ofaa349. doi: 10.1093/ofid/ofaa349. eCollection 2020 Sep.

3

Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.患者患有多重耐药铜绿假单胞菌脑膜炎，连续输注头孢他洛滨-他唑巴坦可使头孢他洛滨在脑脊液中达到高浓度。

Infection. 2021 Apr;49(2):355-359. doi: 10.1007/s15010-020-01510-8. Epub 2020 Aug 29.

4

Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data.革兰氏阴性菌血症中治疗困难耐药对死亡率的影响：全国监测数据的回顾性分析。

Clin Infect Dis. 2020 Dec 3;71(9):e487-e496. doi: 10.1093/cid/ciaa084.

5

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.头孢他啶-阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界经验

Open Forum Infect Dis. 2019 Dec 6;6(12):ofz522. doi: 10.1093/ofid/ofz522. eCollection 2019 Dec.

6

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.头孢他洛赞/他唑巴坦与多粘菌素或基于氨基糖苷类的方案治疗耐多药铜绿假单胞菌的比较

Clin Infect Dis. 2020 Jul 11;71(2):304-310. doi: 10.1093/cid/ciz816.

7

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.RESTORE-IMI 1 研究：一项比较亚胺培南/雷巴他定与多黏菌素 E 联合亚胺培南治疗对亚胺培南耐药的细菌感染患者的疗效和安全性的多中心、随机、双盲试验。

Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530.

8

Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.头孢他啶-阿维巴坦治疗新生儿和<5 岁儿童广泛耐药或全耐药肺炎克雷伯菌感染

Pediatr Infect Dis J. 2019 Aug;38(8):812-815. doi: 10.1097/INF.0000000000002344.

9

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.美罗培南-巴坦与最佳可用疗法治疗耐碳青霉烯类肠杆菌科细菌感染患者的疗效和安全性：TANGO II随机临床试验

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

10

Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR : Case report and review of the literature.头孢洛扎-他唑巴坦与磷霉素用于广泛耐药菌引起的耳源性脑膜炎的挽救治疗：病例报告及文献复习

IDCases. 2018 Aug 31;14:e00451. doi: 10.1016/j.idcr.2018.e00451. eCollection 2018.

多药耐药性脑膜炎治疗期间头孢洛扎与他唑巴坦的血浆和脑脊液治疗药物监测

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Meningitis.

作者信息

McCreary Erin K, Byers Karin E, Fernandes Carolyn, Kline Ellen G, Nicolau David P, Shields Ryan K

机构信息

Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Center for Anti-Infective Research and Development, Hartford, Connecticut, USA.

出版信息

Open Forum Infect Dis. 2020 Nov 12;7(12):ofaa549. doi: 10.1093/ofid/ofaa549. eCollection 2020 Dec.

DOI:10.1093/ofid/ofaa549

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7751399/

Abstract

We report a case of multidrug-resistant meningitis treated with ceftolozane-tazobactam with concomitant therapeutic drug monitoring of plasma and cerebral spinal fluid. The data suggest that ceftolozane-tazobactam may be an option for select central nervous system infections; however, treatment decisions should be interpreted on a case-by-case basis.

摘要

我们报告了1例使用头孢洛扎/他唑巴坦治疗的耐多药脑膜炎病例，并对血浆和脑脊液进行了伴随治疗药物监测。数据表明，头孢洛扎/他唑巴坦可能是某些中枢神经系统感染的一种治疗选择；然而，治疗决策应根据具体病例进行解读。